Announcement under Regulation 30 (LODR)-Newspaper Publication
Dear Sirs, Sub.: Submission of copies of published Unaudited Consolidated Financial Results In continuation of our letter dated July 27, 2018, we enclose the copies of the Unaudited Consolidated Financial Results for the quarter ended June 30, 2018 published on July 28, 2018 in MINT (English) and HINDUSTAN (Hindi). This is for information and records. Intimation Pursuant To Regulation 57(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Payment Of Interest On Non-Convertible Debentures
Dear Sirs, This is to certify that the Company has duly made the payment of half yearly interest on Non- Convertible Debentures issued on private placement basis on due date as per the details below. Sr. No. Series ISIN Nos. Due Date Payment Date Remarks 1 STRPP I INE700A07014 July 27, 2018 July 27, 2018 Payment of 3rd Semi-Annual Interest...
Jubilant Life Q1 profit rises 39% at 200.37 crore
Jubilant Life Sciences reported a 39.42% rise in its consolidated net profit to 200.37 crore for the first quarter, mainly on account of robust sales in the pharma segment Updates On Subsidiary
We wish to now inform you that: 1.The board of directors of the Company has taken on record the resolution dated July 23, 2018 passed by the board of directors of JPL recording that the aforementioned evaluation process is on-going and that any fund raising which may be undertaken by JPL will be by way of an IPO and that the maximum dilution of the Company's shareholding in JPL in the IPO (including any sale of shares of JPL by the Company)... Quarterly Results For The Quarter Ended June 30, 2018
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2018 were approved by the Board of Directors of the Company at its meeting held today at 1.00 p.m. and concluded at 2.45 p.m.... Announcement under Regulation 30 (LODR)-Newspaper Publication
Sub.: Submission of copies of newspaper advertisements In continuation of our letter dated July 20, 2018, we enclose copies of the advertisements published on July 21, 2018, in MINT (English) and HINDUSTAN (Hindi) with respect to notice of the Board Meeting scheduled to be held on July 27, 2018. This is for information and record. Communication Pertaining To I-131 MIBG OPTIMUM Trials.
We enclose a communication pertaining to I-131 MIBG OPTIMUM Trials. This is for your kind information and record. Shareholding for the Period Ended June 30, 2018
Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here Schedule Of Investor Conference Call For Jubilant Life Sciences Limited - Unaudited Financial Results For The Quarter Ended June 30, 2018
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on July 27, 2018 after submission of the financial results for the quarter ended June 30, 2018 to the Stock Exchanges. Details of the Conference Call are attached. This is for information and record. Intimation Of Board Meeting - July 27, 2018
In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, July 27, 2018, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2018.